Cargando…
Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a plann...
Autores principales: | Horwitz, S., Coiffier, B., Foss, F., Prince, H. M., Sokol, L., Greenwood, M., Caballero, D., Morschhauser, F., Pinter-Brown, L., Iyer, S. P., Shustov, A., Nichols, J., Balser, J., Balser, B., Pro, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374388/ https://www.ncbi.nlm.nih.gov/pubmed/25605745 http://dx.doi.org/10.1093/annonc/mdv010 |
Ejemplares similares
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
por: Coiffier, Bertrand, et al.
Publicado: (2014) -
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
por: Pro, Barbara, et al.
Publicado: (2016) -
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014) -
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2016) -
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2017)